Clinicopathologic and prognostic factors in short- and long-term surviving dogs with protein-losing enteropathy by Gianella, Paola et al.
This full text was downloaded from iris - AperTO: https://iris.unito.it/
iris - AperTO
University of Turin’s Institutional Research Information System and Open Access Institutional Repository
This is the author's final version of the contribution published as:
Gianella, Paola; Lotti, Ugo; Bellino, Claudio; Bresciani, Francesca; Cagnasso,
Aurelio; Fracassi, Federico; D’Angelo, Antonio; Pietra, Marco.
Clinicopathologic and prognostic factors in short- and long-term surviving
dogs with protein-losing enteropathy. SCHWEIZER ARCHIV FUR
TIERHEILKUNDE. 159 (3) pp: 163-169.
DOI: 10.17236/sat00108
The publisher's version is available at:
http://sat.gstsvs.ch/de/pubmed/?doi=10.17236/sat00108
When citing, please refer to the published version.
Link to this full text:
http://hdl.handle.net/
Introduction 1 
Protein-losing enteropathy (PLE) in dogs results from severe small intestinal disease that allows leakage of protein into 2 
the intestinal lumen (Dossin and Lavoue, 2011). While panhypoproteinemia associated with loss of albumin and 3 
globulin is the most common clinicopathological abnormality, isolated albumin loss can also be observed (Willard et 4 
al., 2000; Allenspach et al., 2007). The major causes of PLE in dogs are intestinal lymphangiectasia, inflammatory 5 
bowel disease, and lymphoma (Craven et al., 2004; Dandrieux et al., 2013; Nakashima et al., 2015). Because PLE is 6 
associated with decreased serum albumin and increased loss of α1-PI into the gastrointestinal tract, measurement of 7 
serum albumin and fecal α1-proteinase inhibitor (α1-PI) should be included in the diagnostic workup (Murphy, 2003; 8 
Willard, 2013). But since the α1-PI test is not readily available, PLE is usually diagnosed after excluding other 9 
conditions associated with hypoalbuminemia and intestinal histopathology (Dossin and Lavoue, 2011; Willard, 2013). 10 
As compared with chronic enteropathy (CE) with normal albumin (Craven et al., 2004; Allenspach et al., 2007; 11 
Simpson and Jergens, 2011), the prognosis for PLE is usually considered guarded (Allenspach et al., 2007; Dossin and 12 
Lavoue, 2011), and the response to therapy is variable (Simmerson et al., 2014).  13 
Moreover, information on factors that predict outcome of PLE at diagnosis is limited and long-term follow-up data are 14 
lacking. Negative prognostic indicators include medium size (11 to 20 kg), high canine IBD activity index (CIBDAI) 15 
score, a history of vomiting, monocytosis, mildly increased C-reactive protein, normal serum calprotectin and S100A12 16 
concentrations, clonal rearrangement of lymphocyte antigen receptor genes, and intestinal villous blunting (Simmerson 17 
et al., 2014, Equilino et al., 2015; Nakashima et al., 2015). Information on the impact of serum albumin and blood urea 18 
nitrogen concentrations on outcome or survival time is controversial. One study found the survival time to be 19 
significantly influenced by low blood urea nitrogen concentration and severity of hypoalbuminemia (Simmerson et al., 20 
2014), two others reported that elevated blood urea nitrogen concentration and hypoalbuminemia, but not its severity, 21 
were negatively correlated with outcome (Owens et al., 2011; Nakashima et al., 2015), and another found that outcome 22 
or survival time were  not significantly influenced by the initial serum albumin concentration (Equilino et al., 2015). 23 
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Finally, while many dogs with PLE secondary to CE die shortly after initiation of treatment, there are some that achieve 24 
prolonged survival.  25 
The aim of this study was to retrospectively evaluate the differences in clinical and clinicopathological findings 26 
between short- and long-term surviving dogs with PLE secondary to CE at diagnosis and after treatment, and to identify 27 
potential risk factors for poor outcome.  28 
Animals, Material and Methods  29 
History and laboratory findings 30 
We retrospectively reviewed the medical records of dogs with PLE secondary to CE diagnosed at three different 31 
hospitals between January 2009 and November 2013. Inclusion criteria were complete history and physical 32 
examination findings, chronic gastrointestinal signs lasting for more than 3 weeks, hypoalbuminemia (< 2 g/dL) of 33 
gastrointestinal origin with or without hypoglobulinemia, and histopathological evidence of gastrointestinal 34 
inflammation on biopsies collected by endoscopy or laparotomy. Histologic examination was performed in all dogs 35 
according to the histopathological standards of the World Small Animal Veterinary Association (WSAVA) 36 
Gastrointestinal Standardization Group. All biopsies were retrospectively reviewed by a pathologist blinded to the 37 
diagnosis. Chronic canine enteropathy clinical activity index (CCECAI) scores (Allenspach et al., 2007),  complete 38 
blood count, serum biochemistry and coagulation profiles, pancreas specific lipase levels,  serum folate and cobalamin 39 
concentrations were gleaned from the medical records. The reference ranges of the hospital laboratories were 40 
substantially similar. During review of the medical records (February 2015), follow-up information was obtained by 41 
telephone from the owners or referring veterinarians. 42 
Classification and therapy 43 
Dogs were classified as either short-term (STs) or long-term (LTs) survivors if they had died within or were still alive 44 
at 6 months after diagnosis, respectively. Additionally, the medical records were searched for information about the 45 
categorization of CE as food-, antibiotic-, or immunosuppressive-responsive. Dogs that showed complete remission of 46 
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clinical signs while on elimination diet (hydrolysed or restricted antigen diets) were categorized as having food-47 
responsive CE. Dogs that showed complete remission of clinical signs while on tylosin (15 mg/kg, PO, q 12 h) or 48 
metronidazole (10 mg/kg, PO, q 12 h) were categorized as having antibiotic-responsive CE. Dogs that responded to oral 49 
prednisone (1 mg/kg, twice a day for 2-3 weeks before considering dose reduction), oral azathioprine (1 or 2 mg/kg, 50 
once a day), oral chlorambucil (4-6 mg/m
2
, once a day for at least 2 weeks before considering dose reduction), or oral 51 
cyclosporine (5 mg/kg, once a day) were categorized as having immunosuppressive-responsive CE. Dogs were 52 
classified as immunosuppressive-unresponsive if they showed poor or no clinical response to immunosuppressives 53 
(partial disappearance or persistence of clinical signs). 54 
Since the medical records also reported the results of repeated exams at follow-up visits , we set T1 (1 month after 55 
initiation of immunosuppressives) as the time point at which the clinical and clinicopathological information was 56 
complete for the majority of the dogs.  57 
Statistical analysis  58 
Statistical analysis was performed with a commercially available statistical data analysis program (MedCalc

). 59 
Assessment of data for normality was calculated using the D’Agostino-Pearson test. Continuous variables were 60 
expressed as mean (± sd), median (minimum and maximum), percentages or both. Categorical variables were expressed 61 
as normal/negative (0) or abnormal/positive (1). Fisher’s exact test was used to compare between the STs and the LTs 62 
the variables: sex, complaints/clinical signs (small bowel diarrhea, mixed diarrhea, decreased appetite, increased 63 
appetite, vomiting, peripheral edema, ascites, pleural effusion, pruritus, polyuria and polydipsia, lethargy, and muscular 64 
twitching/convulsions), results of the SNAP cPL® test, coagulation profile at T0, and treatments with different types of 65 
immunosuppressives. 66 
Student’s t-test was used to compare between the STs and the LTs the variables: age, body weight, CCECAI scores, 67 
serum albumin, folate concentrations, and lipase activity at T0 and the CCECAI scores, serum albumin and globulin 68 
concentrations  at T1. The Mann-Whitney test was used to compare between the STs and the LTs the variables: number 69 
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of monocytes and platelets, globulin, serum total protein, total cholesterol, blood urea nitrogen, magnesium, cobalamin 70 
and fibrinogen concentrations at T0 and the serum total protein, magnesium and total cholesterol concentration at T1. 71 
Values of P < 0.05 were considered significant. A receiver operating characteristic (ROC) curve was used to select the 72 
optimum cut-off value of the variables at T1 to discriminate the STs from the LTs. 73 
Results  74 
History, physical examination, and CCECAI scores 75 
We reviewed the medical records of 59 dogs with PLE secondary to CE diagnosed between January 1, 2009 and 76 
November 30, 2013. Of these 59 dogs, 19 were classified as STs and 40 as LTs. Among the STs were dogs from 9 77 
different breeds and 2 mixed-breed dogs. Fourteen were male and 5 female. The age range was from 9 months to 13.4 78 
years (mean, 5.9 ± 3.3), and the weight range was from 14 to 40 kg (mean, 23.6 ± 7.3). Table 1 reports the presenting 79 
complaints/clinical signs. The median duration of clinical signs prior to diagnosis was 2 months (range 1-36). The 80 
median survival time was 90 days (range 31 to 180). Among the LTs were dogs from 20 different breeds and 9 mixed-81 
breed dogs. Twenty-two dogs were male and 18 female. The  age  range was from 1 to 11.6 years (mean, 6.5 ± 2.5), 82 
and the weight range was from 1.9 to 45 kg (mean 17.4 ± 12.4). Table 1 reports the presenting complaints/clinical 83 
signs. The median duration of clinical signs prior to diagnosis was 2 months (range 1-36). The median survival time 84 
was 880 days (range 210 to 1,787). No statistically significant differences in sex and age between the two groups were 85 
found at T0; body weight was significantly higher in the STs (P < 0.05). There was no difference in presenting 86 
complaints/clinical signs between the STs and the LTs. 87 
CCECAI scores were available for all dogs at T0, and for all dogs except 1 at T1. No significant differences in the 88 
CCECAI scores between the groups were found at T0; at T1 the CCECAI score was significantly higher in the STs 89 
(Figure 1).  90 
Clinicopathological findings 91 
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Tables 2 and 3 present the clinicopathological findings and the number of dogs that had undergone testing, respectively. 92 
At T0, no statistically significant differences between the two groups were found for: number of monocytes and 93 
platelets, serum albumin, globulin, total protein, total cholesterol, magnesium, cobalamin, folate and fibrinogen 94 
concentrations, lipase activity, results of the SNAP cPL® test, and coagulation profile. Blood urea nitrogen 95 
concentrations were significantly higher in the STs (P < 0.05). At T1, albumin, serum total protein and total cholesterol 96 
concentrations were significantly lower in the STs (P < 0.01).  97 
Gastrointestinal histopathology results 98 
Gastroduodenoscopy was performed in 58 dogs. Additional ileoscopy and colonoscopy were performed in 14 and 28 99 
dogs, respectively. Laparotomy was performed in 1 dog. Tissue quality was classified as adequate in all cases. 100 
Moderate to marked histopathologic abnormalities in the small intestine were found in all dogs. Lymphocytic-101 
plasmacytic inflammation (50 dogs) and  lymphangiectasia (28 dogs) were the most common abnormalities. Moderate 102 
to severe lymphocytic-plasmacytic colonic inflammation was found in 24 dogs. 103 
Treatment and outcome 104 
No significant differences in the treatments with different types of immunosuppressive therapies were found between 105 
the two groups. Based on their response, all STs were categorized as immunosuppressive-unresponsive. Among the 106 
LTs, 32 dogs were categorized as immunosuppressive, 1 and 1 each as  food- and antibiotic-responsive CE, 107 
respectively; 6 dogs were categorized as immunosuppressive-unresponsive. 108 
Follow-up information was available for all dogs. Thirty-three dogs (55.9%; 31 with immunosuppressive-responsive 109 
CE; 1 with food-responsive CE; 1 with antibiotic-responsive CE) were alive at the time of medical record review (73 110 
months), and 26 (44.1%; 19/19 STs and 7/40 LTs with immunosuppressive-responsive CE) had died because of PLE-111 
related complications. The main cause of death was deterioration of clinical conditions presumably due to 112 
malabsorption. A cut-off CCECAI score of > 5 at T1 was found to be the best predictor for poor outcome (Figure 2). 113 
Discussion  114 
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With this retrospective multicenter study we compared the clinical and clinicopathological findings of 59 short- and 115 
long-term surviving dogs with PLE secondary to CE, and investigated potential prognostic factors. Consistent with 116 
previous observations, the adult dogs of any size were affected by PLE (Allenspach et al., 2007; Lecoindre et al., 2010; 117 
Dossin and Lavoue, 2011; Dandrieux et al., 2013; Simmerson et al., 2014), with a predominance of males, however 118 
(Kull et al., 2001; Simmerson et al., 2014). Medium size (11 to 20 kg) has recently been reported as a negative 119 
prognostic indicator (Equilino et al., 2015). When we compared the two groups, we observed that body weight was 120 
significantly higher among the STs. This might simply reflect the type of study population or suggest that large breed 121 
dogs might be affected by more severe forms of PLE. 122 
Small bowel diarrhea and decreased appetite were the most common historical complaints in both groups. A recent 123 
retrospective study found that vomiting was a negative prognostic factor (Simmerson et al., 2014), however, we noted 124 
no significant differences in the presenting complaints/clinical signs between the two groups at T0. As seen also in our 125 
sample, ascites or pleural effusion are common complaints or physical examination findings in dogs with PLE 126 
(Allenspach et al., 2007, Lecoindre et al., 2010) but they do not seem to be negative prognostic indicators (Simmerson 127 
et al., 2014). Activity indices for assessing disease severity can also be used as prognostic markers (Jergens et al., 2003; 128 
Allenspach et al., 2007). According to one study, CCECAI ≥12 at diagnosis predicted refractoriness to treatment and 129 
euthanasia within 3 years (Allenspach et al., 2007). To the contrary, in our and in a recent study (Equilino et al., 2015), 130 
outcome or survival time were not significantly influenced by activity indices at diagnosis.  131 
The only significant difference in pathologic variables between the two groups at T0 was the blood urea nitrogen 132 
concentration, which  can be influenced by dehydration, renal failure or severe GI protein loss. But because we had no 133 
information about prerenal and renal azotemia values in these PLE dogs, this result should be interpreted with caution. 134 
Furthermore, the retrospective design of the present study is an additional limitation. Several variables tested at T0 135 
were not available at T1 for all dogs, and treatments were not strictly standardized. That said, collectively, our results 136 
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may support the hypothesis that the severity of clinical signs and the majority of serum biochemistry and coagulation 137 
profile findings at diagnosis do not appear to correlate with outcome.   138 
The prognosis for dogs with PLE in the current veterinary literature is guarded (Allenspach et al., 2007; Dossin and 139 
Lavoue, 2011). Except for a recent retrospective study (Simmerson et al., 2014), there are few reports of survival data 140 
for dogs with PLE (Craven et al., 2009; Simmerson et al., 2009; Dijkstra et al., 2010;  Goodwin et al., 2011; Owens et 141 
al., 2011; Equilino et al., 2015).
 
Although 32.2% of the dogs had died within 6 months of diagnosis, a greater 142 
proportion (55.9%) was still alive at the time of manuscript preparation, suggesting that not only PLE-affected 143 
Yorkshire Terriers, but also other PLE-affected breeds may experience remission of clinical signs and prolonged 144 
survival despite severity of clinicopathologic findings at diagnosis, as recently described (Equilino et al., 2015).  145 
To our knowledge, no long-term data on the follow-up of dogs with PLE exist. At T1 (6 months follow-up) the 146 
CCECAI scores were higher and the albumin, total protein, and total cholesterol concentrations all lower in the STs. 147 
Moreover, the dogs with a CCECAI score > 5 were more likely to die within 6 months of initial diagnosis. Since these 148 
variables at T0 did not significantly influence the outcome, they might simply reflect a poor response to therapy. 149 
Finally, since all STs were categorized as immunosuppressive-unresponsive, it is reasonable to assume that a poor 150 
response to therapy is a poor prognostic indicator. Indeed, survival time was shorter in the dogs with high CCECAI 151 
scores at T1 and that were unresponsive  to therapy.  152 
In conclusion, the clinical outcomes of PLE are variable, with the majority of the dogs having prolonged survival 153 
despite the severity of clinicopathological findings at diagnosis.  154 
 155 
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 228 
 229 
Table 1. List of presenting complaints/clinical signs at diagnosis (T0) in short-term (ST) and long-term (LT) survivors. 230 
 231 
Variables STs  
n/t 
LTs 
n/t 
Small bowel diarrhea 19/19 39/40 
Mixed diarrhea 5/19 14/40 
Decreased appetite 13/19 22/40 
Increased appetite 1/19 3/40 
Vomiting 9/19 24/40 
Peripheral edema 1/19 5/40 
Ascites 6/19 20/40 
Pleural effusion - 3/40 
Pruritus 1/19 4/40 
Polyuria and polydipsia 4/19 5/40 
Lethargy 2/19 8/40 
Muscular twitching/convulsion 1/19 4/40 
n= number of dogs showing the complaint/clinical sign 232 
t= total number of dogs 233 
 234 
 235 
 236 
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Table 2. Summary of laboratory results at diagnosis (T0) in short-term (ST) and long-term (LT) survivors 237 
 238 
 239 
 240 
 241 
 242 
 243 
 244 
 245 
 246 
 247 
 248 
 249 
 250 
 251 
 252 
 253 
 254 
 255 
 256 
 STs LTs  
Variables Positive or 
abnormal 
Mean (±SD) Positive or 
abnormal 
Mean (±SD) Reference values 
Albumin - 1.49 (±0.42) g/dL - 1.45 (±0.31) g/dL 2.80-3.70 g/dL 
Globulin - 2.08 (±0.87) g/dL - 1.88 (±0.61) g/dL 2.80-4.20 g/dL 
Total Protein - 3.57 (±0.97) g/dL - 3.32 (±0.75) g/dL 5.60-7.90 g/dL 
Total Cholesterol - 118 (±54)  mg/dL - 122 (±48)  mg/dL 140-350 mg/dL 
Magnesium - 1.67 (±0.86)  mg/dL - 1.88 (±1.90)  mg/dL 1.60-3.20 mg/dL 
Blood Urea Nitrogen - 37.62 (±18.65)  mg/dL - 28.72 (±17.32)  mg/dL 18-55 mg/dL 
Cobalamin - 219 (±128)  ng/L - 229 (±107)  ng/L 250-730 ng/L 
Folate - 9.95 (±5.80)  µg/L - 10.42 (±5.90)  µg/L 7-17 µg/L 
Fibrinogen - 450 (±146)  mg/dL - 555 (±225)  mg/dL 150-450 mg/dL 
Lipase - 191 (±123)  U/L - 302 (±205)  U/L 70-700 U/L 
SNAP cPL® 2 - 3 - - 
Number of platelets - 463,684 (±218,761) 
 
cells/µL 
- 426,056 (±252,977) 
cells/µL  
150,000-500,000
 
cells/µL 
Number of monocytes - 686 (±482)  
 
cells/µL 
- 634 (±396)  
 
cells/µL 
100-1400 
 
cells/µL 
Coagulation profile 9 - 10 - - 
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Table 3. Summary of clinicopathological variables tested at diagnosis (T0) and 1 month after initiation of immunosuppressive therapy 257 
(T1) in short- term (ST) and long-term (LT) survivors. 258 
 259 
 T0 T1 
Variable 
STs  
n/t 
LTs  
n/t 
STs  
n/t 
LTs  
n/t 
Albumin 19/19 40/40 18/19 40/40 
Globulin 19/19 40/40 18/19 39/40 
Total Protein 19/19 40/40 18/19 39/40 
Total Cholesterol 19/19 38/40 13/19 31/40 
Magnesium 9/19 26/40 6/19 18/40 
Blood Urea Nitrogen 19/19 37/40 - - 
Cobalamin 13/19 30/40 - - 
Folate 13/19 32/40 - - 
Fibrinogen 5/19 16/40 - - 
Lipase 10/19 27/40 - - 
SNAP cPL® 5/19 17/40 - - 
Number of platelets 19/19 38/40 - - 
Number of monocytes 18/19 32/40 - - 
Coagulation profile 6/19 13/40 - - 
n=number of dogs in which the variable was measured 260 
t=total number of dogs 261 
 262 
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Figure 1. Comparison of canine chronic enteropathy activity scoring index (CCECAI) between short-term (ST) and long-term (LT) 263 
survivors at T0 and T1. 264 
 265 
 266 
 267 
 268 
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Figure 2. The receiver operating characteristic (ROC) curve used to select the optimum cut-off value of the variable CCECAI associated 269 
with survival to discriminate between short-term (ST) and long-term (LT) survivors. 270 
 271 
Sensitivity: 77.8 272 
Specificity: 87.5 273 
Criterion: >5 274 
Area under the ROC curve: 0.828 275 
Standard error: 0.0672 276 
95% Confidence interval: 0.706 to 0.914 277 
Z statistic: 4.878 278 
Significance level P <0.0001 279 
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